Literature DB >> 10733171

Neutralizing monoclonal antibody to the E1 glycoprotein epitope of rubella virus mediates virus arrest in VERO cells.

P Cordoba1, S Grutadauria, C Cuffini, M Zapata.   

Abstract

The best-known mechanism of action of antibody-mediated virus neutralization is to impede the entrance of viruses to host cells, as determined by neutralization assays. Antibodies may also inhibit the exit of rubella virus (RV) from infected host cells; in this case, the interaction of the antibodies with their domains must occur on the plasma membrane, because antibodies cannot enter the cells. In the present study, we were able to block temporally the exit of virions from RV-infected cells by the binding of monoclonal antibody (mAb) H3 to their surface. The objective was accomplished in three steps: first, we determined the duration of the viral replication cycle; then we established the kinetics of the presence of the domains defined by our mAbs in the cytoplasm of RV-infected VERO cells; and, finally, we assessed the release of viral particles to the supernatant of infected VERO cells in the presence or absence of mAbs or positive and negative mice sera. RV-specific mice sera and mAb H3, which binds to the amino acid sequence 208-239 of the RV-E1 glycoprotein, were able to delay for 24 hours the release of virions from infected cultures, suggesting that the reaction of mAb H3 with its epitope may arrest any change necessary for the assembly and/or release of virions. In conclusion, the neutralizing domain recognized by mAb induces antibodies that can block the viral replication by several mechanisms of action, such as the obstruction of virus entry into cells and the delay of viral release. All of these mechanisms are intimately involved in the critical virus-host cell interactions that allow self-limitation of the infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733171     DOI: 10.1089/vim.2000.13.83

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  7 in total

1.  Chimeric derivatives of hepatitis B virus core particles carrying major epitopes of the rubella virus E1 glycoprotein.

Authors:  Dace Skrastina; Ivars Petrovskis; Rasa Petraityte; Irina Sominskaya; Velta Ose; Ilva Lieknina; Janis Bogans; Kestutis Sasnauskas; Paul Pumpens
Journal:  Clin Vaccine Immunol       Date:  2013-09-04

2.  Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.

Authors:  Jing Jin; Nathan M Liss; Dong-Hua Chen; Maofu Liao; Julie M Fox; Raeann M Shimak; Rachel H Fong; Daniel Chafets; Sonia Bakkour; Sheila Keating; Marina E Fomin; Marcus O Muench; Michael B Sherman; Benjamin J Doranz; Michael S Diamond; Graham Simmons
Journal:  Cell Rep       Date:  2015-12-10       Impact factor: 9.423

3.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

4.  Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane.

Authors:  Jing Jin; Jesús G Galaz-Montoya; Michael B Sherman; Stella Y Sun; Cynthia S Goldsmith; Eileen T O'Toole; Larry Ackerman; Lars-Anders Carlson; Scott C Weaver; Wah Chiu; Graham Simmons
Journal:  Cell Host Microbe       Date:  2018-08-23       Impact factor: 21.023

5.  Functions of Antibodies.

Authors:  Donald N Forthal
Journal:  Microbiol Spectr       Date:  2014-08-15

Review 6.  Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus.

Authors:  Jing Jin; Graham Simmons
Journal:  Viruses       Date:  2019-03-28       Impact factor: 5.048

7.  Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors.

Authors:  Mehmet Sahin; Melissa M Remy; Benedict Fallet; Rami Sommerstein; Marianna Florova; Anna Langner; Katja Klausz; Tobias Straub; Mario Kreutzfeldt; Ingrid Wagner; Cinzia T Schmidt; Pauline Malinge; Giovanni Magistrelli; Shozo Izui; Hanspeter Pircher; J Sjef Verbeek; Doron Merkler; Matthias Peipp; Daniel D Pinschewer
Journal:  Cell Rep       Date:  2022-02-01       Impact factor: 9.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.